In the H1975 nude mice model, apatinib combined with gefitinib could inhibit tumor growth, inhibited the activation of EGFR and VEGFR2, and decreased the level of CD31 and vascular endothelial growth factor A. In patients with gefitinib resistance, apatinib combined with gefitinib achieved a median PFS of 4.60 months.16 These findings suggest that apatinib is expected to be an anti‐tumor drug for NSCLC, and combination chemotherapy or first‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) may be more effective. Here, KDR is linked to non-small cell lung carcinoma.